• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Metrion Biosciences joins human pain research consortium

Metrion Biosciences joins human pain research consortium

August 29, 2016
CenterWatch Staff

Metrion Biosciences, a specialist ion-channel and drug discovery CRO, has entered into an agreement with a network of partners to evaluate the use of primary human dorsal root ganglion (hDRG) neurons in pain research. This Consortium comprises the University of Glasgow, the University of St. Andrews, NHS Greater Glasgow & Clyde (NHS-GGC), Metrion Biosciences, the Grünenthal Group in Germany, and the U.K. National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), with vital support and facilitation by NHS Blood & Transplant (Scotland). 

The ultimate aim of the project is to enhance research efficiency by putting in place a system whereby high quality and viable human DRG neurons can be supplied to both industrial and academic researchers, thereby partially superseding current methods involving isolated cells or tissues from animals, or in vivo animal testing. Successful implementation of the system will increase our understanding of the human system, facilitating drug target identification and supporting more rapid development of novel pain therapeutics. 

The Consortium anticipates that the project will lead to the development of a successful human sensory neuronal model for improved mechanistic understanding and compound screening, which will aid in advancing the speed and quality of research into new pain therapeutics. Better understanding of human DRG neurons may also facilitate the development of stem cell-derived sensory neurons for use in high throughput and high content screening of new drug candidates. A successful outcome of the collaboration will also include a contribution to the reduction in the use of animals in pain research. 

Metrion is supporting the project as an industrial sponsor alongside Grünenthal, a family-owned, international research-driven pharmaceutical company headquartered in Aachen, Germany. Metrion is taking over a role previously undertaken by Pfizer-Neusentis, and will be responsible for evaluation and functional characterization of human nerve cells. The project, entitled “Developing an ethical, sustainable, human sensory neuron cell culture model for use in therapeutic pain research,” also known as DRGNET, is headed by the University of Glasgow, which has received funding from the NC3Rs as part of their CRACK IT Challenges open innovation initiative. 

Supported by NHS Blood & Transplant and integrated into their pathways for life-saving organ retrieval, and only with specific authorization from donors’ families, surgical staff from NHS-GGC will retrieve human DRGs from organ transplant donors, and research staff from the University and their partners will extract viable sensory neurons. Protocol development has been approved by the West of Scotland Research Ethics Service (WoSRES). Metrion will undertake functional characterization of sensory neurons dissociated from fresh human DRGs, in particular the distribution and function of specific ion channels and receptors. 

The intellectual property rights to the evaluation results will be owned by the University of Glasgow, and, as a sponsor, Metrion will have rights to use the data for its own research and will retain rights to any proprietary testing of compounds done within its laboratories. 

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing